Concepts (188)
Concepts are derived automatically from a person's publications.
The timeline below shows the dates (blue tick marks) of publications associated with David Grinblatt's top concepts. The average publication date for each concept is shown as a red circle, illustrating changes in the primary topics that David Grinblatt has written about over time.
Lymphoma, Non-HodgkinHematopoietic Stem Cell TransplantationTopotecanBlood Coagulation DisordersBlood Coagulation Factor InhibitorsAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and overMyelodysplastic SyndromesRituximabAntimetabolites, AntineoplasticAzacitidineProspective StudiesLeukemia, Lymphocytic, Chronic, B-CellRegistriesLeukemia, Myeloid, AcuteLaboratoriesPathology, MolecularDrug IndustryAlemtuzumabAntineoplastic Agents, Immunological
To see the data from this visualization as text,
click here.
| Name | Number of Publications | First Publication Year | Most Recent Publication Year | Average Publication Date |
|---|
| Lymphoma, Non-Hodgkin | 4 | 1999 | 2010 | November 2004 |
| Hematopoietic Stem Cell Transplantation | 9 | 1998 | 2023 | April 2005 |
| Topotecan | 2 | 2005 | 2009 | May 2007 |
| Blood Coagulation Disorders | 1 | 2008 | 2008 | November 2008 |
| Blood Coagulation Factor Inhibitors | 1 | 2008 | 2008 | November 2008 |
| Antineoplastic Combined Chemotherapy Protocols | 12 | 1992 | 2025 | June 2009 |
| Aged, 80 and over | 10 | 2005 | 2025 | March 2015 |
| Myelodysplastic Syndromes | 7 | 2005 | 2023 | June 2015 |
| Rituximab | 3 | 2010 | 2020 | December 2015 |
| Antimetabolites, Antineoplastic | 2 | 2014 | 2017 | March 2016 |
| Azacitidine | 2 | 2014 | 2017 | March 2016 |
| Prospective Studies | 10 | 1999 | 2023 | May 2016 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2013 | 2020 | February 2017 |
| Registries | 8 | 2014 | 2023 | August 2019 |
| Leukemia, Myeloid, Acute | 2 | 2016 | 2023 | December 2019 |
| Laboratories | 1 | 2023 | 2023 | July 2023 |
| Pathology, Molecular | 1 | 2023 | 2023 | July 2023 |
| Drug Industry | 1 | 2023 | 2023 | August 2023 |
| Alemtuzumab | 1 | 2025 | 2025 | February 2025 |
| Antineoplastic Agents, Immunological | 1 | 2025 | 2025 | February 2025 |
To return to the timeline,
click here.